- Yuting Guo, Juan Chen, Nan Liu, Zheng Liu, Bimin Shi, Hong Sun. Association of Circulating TXNIP Levels with Fatty Liver in Newly Diagnosed Type 2 Diabetes Mellitus. DMSO 2022;Volume 15:225

- Sadra Samavarchi Tehrani, Golnaz Goodarzi, Ghodratollah Panahi, Fahimeh Zamani-Garmsiri, Reza Meshkani. The combination of metformin with morin alleviates hepatic steatosis via modulating hepatic lipid metabolism, hepatic inflammation, brown adipose tissue thermogenesis, and white adipose tissue browning in high-fat diet-fed mice. Life Sciences 2023;323:121706

- Satoshi Shinozaki, Toshiyuki Tahara, Kouichi Miura, Alan Kawarai Lefor, Hironori Yamamoto. Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study. Life 2023;13:1327

- Li Chen, Qin Chen, Xueping Chen, Pengli Zhu, Meinan Chen, Wei Wang, Shandong Ye, Mao Zheng. Clinical Application of Metformin Use in Anhui Province, China: A Cross-Sectional Study. JMDH 2023;Volume 16:345

- Mingxiao Luo, Tingting Li, Haiquan Sang. The role of hypoxia-inducible factor 1α in hepatic lipid metabolism. J Mol Med 2023;101:487

- Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Hebatallah M. Saad, Gaber El-Saber Batiha. The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM). Inflammopharmacol 2023;31:1751

- Li Rong, Junyan Zou, Wei Ran, Xiaohong Qi, Yaokai Chen, Hongjuan Cui, Jinjun Guo. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front. Endocrinol. 2023;13

- André J. Scheen. Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD). Diabetes Epidemiology and Management 2023;11:100145

- Jabeur Methnani, Marwa Hajbelgacem, Taieb Ach, Faten Chaieb, Sana Sellami, Ali Bouslama, Monia Zaouali, Asma Omezzine, Ezdine Bouhlel. Effect of Pre-Meal Metformin With or Without an Acute Exercise Bout on Postprandial Lipemic and Glycemic Responses in Metabolic Syndrome Patients: A Randomized, Open Label, Crossover Study. J Cardiovasc Pharmacol Ther 2023;28:107424842311563

- Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Domenico Triggiani, Rossella Donghia, Lucilla Crudele, Roberta Rinaldi, Carlo Sabbà, Vincenzo Triggiani, Giovanni De Pergola, Giuseppina Piazzolla. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients 2022;14:4673

- Janina Senn, Stefan Fischli. Visceral and Ectopic Fat. 2022.

- Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B Patel. Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments. World J Gastroenterol 2023;29:4831

- Mohamed Abouelkheir, Ibrahim Taher, Amira S. R. Eladl, Dalia A. Shabaan, Mona F. M. Soliman, Ahmed E. Taha. Detection and Quantification of Some Ethanol-Producing Bacterial Strains in the Gut of Mouse Model of Non-Alcoholic Fatty Liver Disease: Role of Metformin. Pharmaceuticals 2023;16:658

- Jose Arriola-Montenegro, Renato Beas, Renato Cerna-Viacava, Andres Chaponan-Lavalle, Karla Hernandez Randich, Diego Chambergo-Michilot, Herson Flores Sanga, Pornthira Mutirangura. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease. World J Cardiol 2023;15:328

- Amin Hasanvand. The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases. Inflammopharmacol 2022;30:775
